What is the 13F Pro Quality Score for PLRX?

13F Pro ranks PLIANT THERAPEUTICS, INC. (PLRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PLRX's current score at https://13fpro.ai/research/PLRX (free sign-up required for the full ranking).

Where does 13F Pro source PLRX data?

All PLIANT THERAPEUTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. PLIANT THERAPEUTICS, INC. files with the SEC under CIK 1746473. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PLRX in?

PLIANT THERAPEUTICS, INC. (PLRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PLRX research updated on 13F Pro?

PLRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PLIANT THERAPEUTICS, INC.(PLRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1746473 PLRX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

PLRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for PLIANT THERAPEUTICS, INC. (PLRX), a Healthcare sector company. PLRX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), PLIANT THERAPEUTICS, INC. reports net income of $-20.0M, free cash flow of $-19.2M. Top institutional holders of PLRX by reported 13-F value include TANG CAPITAL MANAGEMENT, CITADEL ADVISORS, Blue Owl Capital Holdings, based on the most recent SEC filings. PLRX trades on the Nasdaq exchange and files with the SEC under CIK 1746473. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PLRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PLIANT THERAPEUTICS, INC. directly from SEC EDGAR. PLIANT THERAPEUTICS, INC.'s 13F Pro composite quality score has ranged between 7 and 40 since 2022, currently 26.1 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

Net Income

Q1 2026

$-20.0M

Free Cash Flow

Q1 2026

$-19.2M

D/E Ratio

Q1 2026

0.00

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$0.00FY 2025

FY22 $9.7MFY23 $1.6MFY24 $0.00FY25 $0.00

Net Income

-171.0% YoY

$-149.3MFY 2025

FY22 $-123.3MFY23 $-161.3MFY24 $210.3MFY25 $-149.3M

Operating Income

+31.5% YoY

$-156.4MFY 2025

FY22 $-127.2MFY23 $-184.1MFY24 $-228.4MFY25 $-156.4M

EPS (Diluted)

+30.0% YoY

$-2.43FY 2025

FY22 $-2.94FY23 $-2.75FY24 $-3.47FY25 $-2.43

Total Assets

-43.3% YoY

$225.2MFY 2025

FY22 $350.6MFY23 $512.2MFY24 $396.9MFY25 $225.2M

Total Debt

-100.0% YoY

$0.00FY 2025

FY22 $9.9MFY23 $10.1MFY24 $30.2MFY25 $0.00

Op. Cash Flow

+17.5% YoY

$-128.3MFY 2025

FY22 $-94.6MFY23 $-116.4MFY24 $-155.5MFY25 $-128.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$0.00	$0.00 -100.0%	$1.6M -83.7%	$9.7M +27.9%	$7.6M -81.9%	$41.8M
Net Income	$-149.3M -171.0%	$210.3M +230.3%	$-161.3M -30.8%	$-123.3M -26.8%	$-97.3M -134.2%	$-41.5M
Operating Income	$-156.4M +31.5%	$-228.4M -24.0%	$-184.1M -44.8%	$-127.2M -30.4%	$-97.5M -134.2%	$-41.6M
EPS (Diluted)	$-2.43 +30.0%	$-3.47 -26.2%	$-2.75 +6.5%	$-2.94 -8.5%	$-2.71 -39.0%	$-1.95
Total Assets	$225.2M -43.3%	$396.9M -22.5%	$512.2M +46.1%	$350.6M +58.5%	$221.2M -25.1%	$295.5M
Total Debt	$0.00 -100.0%	$30.2M +200.5%	$10.1M +1.3%	$9.9M	$0.00	—
Operating Cash Flow	$-128.3M +17.5%	$-155.5M -33.6%	$-116.4M -23.0%	$-94.6M -25.4%	$-75.4M -102.4%	$-37.3M

AI Insight: PLRX Financial Trends

Pliant is burning cash at a decelerating pace with debt eliminated, but revenue remains zero and equity base is eroding.

• Net losses narrowed from $56M in Q1 2025 to $20M in Q1 2026; operating cash burn improved from $49M to $19M.

• Total debt eliminated entirely by Q4 2025 (from $30M), reducing financial obligation.

• Equity declined 58% from $393M (Q2 2024) to $165M (Q1 2026) as cumulative losses compound.

⚠ No revenue generation across entire 10-quarter span; company remains pre-commercial with no visible inflection.

⚠ Equity runway of ~$165M at current $19M quarterly burn implies 8–9 quarters of cash before depletion.

AI Insight: PLRX Ratio Trends

PLRX remains deeply unprofitable with deteriorating returns; modest Q1 2026 ROE recovery masks persistent cash burn and negative ROIC across all periods.

• ROE improved from -87.4% in Q1 2025 to -48.5% in Q1 2026, but remains deeply negative; ROA and ROIC show similar partial recovery.

• Debt-to-equity rose from 0.08 in Q2 2024 to 0.15 in Q3 2025, signaling increased leverage during sustained losses.

⚠ All profitability metrics remain negative: TTM ROE -68.5%, ROA -55.9%, ROIC -72.2%. Company has yet to demonstrate path to positive returns.

⚠ ROIC deteriorated from -49.0% (Q3 2025) to -52.7% (Q1 2026), reversing prior quarter's improvement. Watch for sustained profitability inflection.

Get alerted when PLRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PLIANT THERAPEUTICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PLRX

TANG CAPITAL MANAGEMENT LLC
$7.7M6,143,132 sh
CITADEL ADVISORS LLC
$4.1M3,226,599 sh
Blue Owl Capital Holdings LP
$3.7M2,969,199 sh
ADAR1 Capital Management, LLC
$3.3M2,585,126 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.0M2,343,101 sh
TWO SIGMA INVESTMENTS, LP
$2.8M2,253,138 sh
Monaco Asset Management SAM
$2.4M1,938,747 sh
RENAISSANCE TECHNOLOGIES LLC
$2.3M1,852,842 sh
Prosight Management, LP
$2.1M1,667,600 sh
Woodline Partners LP
$2.1M1,666,830 sh

Fund	Value	Shares
TANG CAPITAL MANAGEMENT LLC	$7.7M	6,143,132
CITADEL ADVISORS LLC	$4.1M	3,226,599
Blue Owl Capital Holdings LP	$3.7M	2,969,199
ADAR1 Capital Management, LLC	$3.3M	2,585,126
VANGUARD CAPITAL MANAGEMENT LLC	$3.0M	2,343,101
TWO SIGMA INVESTMENTS, LP	$2.8M	2,253,138
Monaco Asset Management SAM	$2.4M	1,938,747
RENAISSANCE TECHNOLOGIES LLC	$2.3M	1,852,842
Prosight Management, LP	$2.1M	1,667,600
Woodline Partners LP	$2.1M	1,666,830

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PLRX on your watchlist

Track score changes the day PLIANT THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PLRX a good stock to buy?

13F Pro's AI-powered analysis of PLIANT THERAPEUTICS, INC. (PLRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PLRX are available on the PLRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PLRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PLRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PLIANT THERAPEUTICS, INC.'s investment landscape.